Zymeworks Corp - רווח נקי למניה בארבעת הרבעונים האחרונים ZYME

Zymeworks Inc. diversifies risks by licensing multispecific antibodies to various partners. Production safety is ensured through strict control of bio-waste disposal. Financial stability is based on payments from pharma behemoths, although R&D costs render cash flow unstable. The relative YoY EPS growth over the last 12 months on this GURU.Markets platform chart reflects profit dynamics, where 179.00 represents the current metric value.

This indicator tracks the daily dynamics of rolling trailing twelve-month net earnings per share, enabling the rapid identification of slowing capital growth rates amid inflation. By analyzing the rolling YoY earnings per share change, an investor can assess the commercialization efficiency of Zymeworks Inc. (ZYME) bispecific antibodies, where the peak of zanidatamab clinical trials must transform into a sustainable financial trend.